ArticleJournal of neuro-oncology2025
Dual tumor control and neuroprotective efficacy of Boron Neutron Capture Therapy in orthotopic mouse glioma model.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
introductionBoron Neutron Capture Therapy (BNCT) offers precise tumor targeting in brain tumor treatment. However, its anti-glioma mechanism remains unclear, and radiation safety requires strict dose optimization. PURPOSE: To define the safe therapeutic window for BNCT in the treatment of glioma and elucidate tumor-control mechanisms.
methodsIn vitro: GL261 cell viability assessed via CCK-8 and colony formation assays under varying 10B-BPA concentrations and neutron irradiation durations. In vivo: Orthotopic GL261 glioma models established. Treatment efficacy evaluated by tumor weight, survival analysis, and body weight monitoring. Boron biodistribution measured by ICP-MS. Motor/cognitive function assessed via open field and novel object recognition tests. Key protein expression analyzed by Western blotting in tumors/normal brain tissue.
resultsIn vitro, 10B-BPA alone was non-cytotoxic, but significantly enhanced tumor cell killing when combined with neutron irradiation. In vivo, BNCT treatment (with 10B-BPA dose of 250, [BNCT 250] or 500 mg/kg, [BNCT 500]) reduced tumor weight more effectively than neutron irradiation alone, confirming its enhanced anti-tumor effect. However, only the BNCT 250 alleviated motor impairment in mice. Photon-equivalent dose estimation revealed tumor/normal tissue biological doses of 4.43/1.42 Gy-Eq for BNCT 250 and 8.46/2.57 Gy-Eq for BNCT 500. Furthermore, BNCT 250 significantly increased NeuN and BDNF expression in normal brain tissue and promoted tumor apoptosis by elevating the Bax/Bcl-2 ratio, inducing cytochrome c release, and activating the caspase cascade.
conclusionOptimal BNCT regimen selectively triggered mitochondrial apoptosis in tumors via Bax/Bcl2/caspase cascade, while upregulating NeuN/BDNF in normal brains. This study firstly verified dual tumor control and neuroprotective efficacy of BNCT in vivo.
Indexed as
Identifiers
41199086What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.